Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S-oxprenolol - Actimed Therapeutics

Next Previous
Drug Profile

S-oxprenolol - Actimed Therapeutics

Alternative Names: ACM-002; FDY 8801

Latest Information Update: 06 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actimed Therapeutics
  • Developer Actimed Therapeutics; Faraday Pharmaceuticals
  • Class Antihypertensives; Ethers; Ischaemic heart disorder therapies; Phenoxypropanolamines; Propanolamines; Small molecules
  • Mechanism of Action Beta adrenergic receptor agonists; Beta adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cachexia
  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 04 Sep 2024 S-oxprenolol - Actimed Therapeutics receives Orphan Drug status for Amyotrophic lateral sclerosis in USA
  • 16 Jan 2024 Phase-II clinical trials in Cachexia (unspecified route) prior to January 2024 (Faraday pharmaceuticals pipeline, January 2024)
  • 07 Sep 2023 Preclinical trials in Amyotrophic lateral sclerosis in United Kingdom (unspecified route) prior to September 2023 (Actimed Therapeutics pipeline; September 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top